Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Authors
Keywords
-
Journal
World Journal of Clinical Cases
Volume 3, Issue 7, Pages 545
Publisher
Baishideng Publishing Group Inc.
Online
2017-11-01
DOI
10.12998/wjcc.v3.i7.545
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Varicella-Zoster Virus Infections in Patients Treated With Fingolimod
- (2015) Ann M. Arvin et al. JAMA Neurology
- Patient-centered outcomes: Translating clinical efficacy into benefits on health-related quality of life
- (2015) D. Miller et al. NEUROLOGY
- Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study
- (2014) Chiara Pecori et al. BMC Neurology
- Benefit of Additional Screening for Progressive Multifocal Leukoencephalopathy in Patients With Multiple Sclerosis Taking Natalizumab
- (2014) David C. Landy et al. CLINICAL NEUROPHARMACOLOGY
- Update on Disease-Modifying Treatments for Multiple Sclerosis
- (2014) Michael D. Carrithers CLINICAL THERAPEUTICS
- New management algorithms in multiple sclerosis
- (2014) Per Soelberg Sorensen CURRENT OPINION IN NEUROLOGY
- No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation
- (2014) M. Capobianco et al. EUROPEAN JOURNAL OF NEUROLOGY
- Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study
- (2014) Alberto Gajofatto et al. EUROPEAN NEUROLOGY
- The current role of mitoxantrone in the treatment of multiple sclerosis
- (2014) Eleonora Cocco et al. Expert Review of Neurotherapeutics
- Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
- (2014) Alessandra Lugaresi et al. Expert Review of Neurotherapeutics
- A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
- (2014) Tjalf Ziemssen et al. JOURNAL OF NEUROLOGY
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Aaron E Miller et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
- (2014) Dean M. Wingerchuk et al. MAYO CLINIC PROCEEDINGS
- Significant clinical worsening after natalizumab withdrawal: Predictive factors
- (2014) A Vidal-Jordana et al. Multiple Sclerosis Journal
- Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients
- (2014) Jordi Río et al. Multiple Sclerosis Journal
- Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
- (2014) Manuel A. Friese et al. Nature Reviews Neurology
- Fingolimod after natalizumab and the risk of short-term relapse
- (2014) V. G. Jokubaitis et al. NEUROLOGY
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Management of Multiple Sclerosis During Pregnancy and the Reproductive Years
- (2014) Riley Bove et al. OBSTETRICS AND GYNECOLOGY
- Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
- (2014) Luca Massacesi et al. PLoS One
- Switching From Natalizumab to Fingolimod in Multiple Sclerosis
- (2014) Mikael Cohen et al. JAMA Neurology
- Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
- (2013) Deepak MW Balak et al. BMC Neurology
- Requirement for safety monitoring for approved multiple sclerosis therapies: an overview
- (2013) P. S. Rommer et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance
- (2013) Ellen Lu et al. Expert Review of Neurotherapeutics
- Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
- (2013) G. Edan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
- (2013) Maria Pia Sormani et al. LANCET NEUROLOGY
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review
- (2013) Charity Evans et al. NEUROEPIDEMIOLOGY
- Incidence of multiple sclerosis in multiple racial and ethnic groups
- (2013) A. Langer-Gould et al. NEUROLOGY
- PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
- (2013) Bob W. van Oosten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stoppers and non-starters of disease-modifying treatment in multiple sclerosis
- (2012) N. Grytten et al. ACTA NEUROLOGICA SCANDINAVICA
- Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study
- (2012) Charity Evans et al. CLINICAL THERAPEUTICS
- Multiple sclerosis and pregnancy: therapeutic considerations
- (2012) Maria K. Houtchens et al. JOURNAL OF NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
- (2012) Roger Jungedal et al. Multiple Sclerosis Journal
- Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome
- (2012) Giancarlo Comi et al. Multiple Sclerosis Journal
- Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
- (2012) Anke Vennegoor et al. Multiple Sclerosis Journal
- Scoring treatment response in patients with relapsing multiple sclerosis
- (2012) MP Sormani et al. Multiple Sclerosis Journal
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
- (2011) R. Philip Kinkel ARCHIVES OF NEUROLOGY
- Cancer and multiple sclerosis in the era of disease-modifying treatments
- (2011) Christine Lebrun et al. JOURNAL OF NEUROLOGY
- Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial
- (2011) G. Edan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis
- (2011) S. Simpson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity
- (2011) Małgorzata Siger et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
- (2011) M. P. Sormani et al. NEUROLOGY
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
- (2010) Chris H Polman et al. LANCET NEUROLOGY
- Assessing changes in relapse rates in multiple sclerosis
- (2010) Seidu Inusah et al. Multiple Sclerosis Journal
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
- (2009) G Comi et al. LANCET
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
- (2009) Roisín Lonergan et al. Multiple Sclerosis Journal
- A reassessment of the plateauing relationship between T2 lesion load and disability in MS
- (2009) M. P. Sormani et al. NEUROLOGY
- Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study
- (2009) D. Cadavid et al. NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis
- (2008) A Gajofatto et al. Multiple Sclerosis Journal
- MRI as an outcome in multiple sclerosis clinical trials
- (2008) M. Daumer et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started